Michael Nagel
Corneal and Contact Management · Willmar, MNNPI 1548219512
Payments from drug & device makers
What this record shows
Johnson & Johnson Surgical Vision, Inc. accounts for 67.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $658 and has fallen 97.1% since, to $19 in 2025.
Across 13 payments — averaging $59.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$515
- The Cameron-ehlen Group, Inc.$88
- Alcon$75
- Lensar, Inc.$30
- Sight Sciences, Inc.$25
- Tarsus Pharmaceuticals, Inc.$19
- plus $15 from 1 others
What the payments were for
- Travel & lodging$39551%
- Food & beverage$37249%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 4 | $515 |
| The Cameron-ehlen Group, Inc. | 2 | $88 |
| Alcon | 2 | $75 |
| Lensar, Inc. | 2 | $30 |
| Sight Sciences, Inc. | 1 | $25 |
| Tarsus Pharmaceuticals, Inc. | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$767 in reported general payments places this provider in the 65th percentile of 30 corneal and contact management providers in Minnesota.
See all corneal and contact management providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 45 | $32,815 |
| LumiganBimatoprost | 36 | $19,797 |
| Latanoprost | 599 | $9,502 |
| Brimonidine Tartrate | 47 | $8,389 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 147 | $2,836 |
| Prednisolone Acetate | 75 | $2,691 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $2,453 |
| Timolol Maleate | 210 | $2,412 |
| TafluprostTafluprost/Pf | 15 | $2,241 |
| Cyclosporine | 12 | $1,548 |
| Dorzolamide Hcl | 58 | $1,217 |
| ValacyclovirValacyclovir Hcl | 42 | $886 |
| Ketorolac Tromethamine | 22 | $465 |
| Levobunolol Hcl | 11 | $331 |
| Ofloxacin | 17 | $310 |
Paid to pharmacies, not to this prescriber.
Other corneal and contact management in Willmar
- Michael NovakWillmar$2K
- Thomas LenzWillmar$458
- Ahmad FahmyMinneapolis$222K
- Scott HauswirthBloomington$73K
- Mark BuboltzBloomington$6K
- Tina McCartyFridley$3K
- Thomas EltonEdina$2K
- Alicia AlvaradoFridley$2K
- Johnna HobbsBloomington$2K
- Robert DingaOakdale$962
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.